<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717687</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE</org_study_id>
    <nct_id>NCT04717687</nct_id>
  </id_info>
  <brief_title>Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Étude Pilote de l'évaluation de la Technique de l'électroporation irréversible Dans le Cholangiocarcinome Infiltrant périhilaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sport &amp; Collection 2019</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the feasibility of irreversible electroporation in the&#xD;
      treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the&#xD;
      unresectable part of the tumor to make it more accessible for a secondary surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of the technique, being the realisation of the irreversible electroporation.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Interventional Imaging</condition>
  <arm_group>
    <arm_group_label>Electrodes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irreversible electroporation</intervention_name>
    <description>Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.</description>
    <arm_group_label>Electrodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years old&#xD;
&#xD;
          -  Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered&#xD;
             as unresectable on the pre-operative imaging data performed during the month preceding&#xD;
             inclusion, and in multidisciplinary consultation meeting specialised in digestive&#xD;
             oncology&#xD;
&#xD;
          -  Histologically (or cytologically) proven tumor of less than 4 cm of the largest&#xD;
             diameter&#xD;
&#xD;
          -  World Health Organization Performance Index 0 or 1&#xD;
&#xD;
          -  No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix&#xD;
             cancer or any other cancer in complete remission for more than 3 years&#xD;
&#xD;
          -  No prior radiotherapy for cholangiocarcinoma&#xD;
&#xD;
          -  Biological analyses performed during the month preceding inclusion : hepatic enzymes&#xD;
             (AST and ALT &lt;3N), preserved renal function (creatinine clearance according to&#xD;
             Modification of the Diet in Renal Disease &gt;50ml/min); bilirubin &lt;3N; bile drainage&#xD;
             must be correct with a bilirubin below 3N , with or without drainage/prothesis,&#xD;
             hemoglobin &gt;9g/dL, leucocytes &gt;3500/mm3, platelets &gt;75000/mm3, prothrombin rate &gt;70%&#xD;
&#xD;
          -  Signature of the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging&#xD;
             data&#xD;
&#xD;
          -  Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...)&#xD;
             visceral failure, in the 6 months preceding the study&#xD;
&#xD;
          -  Visceral metastases or peritoneal carcinosis&#xD;
&#xD;
          -  History of cancers except if remission for more than 3 years, in-situ cancer,&#xD;
             epidermoid or baso-cellular cancer&#xD;
&#xD;
          -  Metal biliary prothesis non extractable&#xD;
&#xD;
          -  Patient with history of epileptic events&#xD;
&#xD;
          -  History of myocard infarction for less than 6 months&#xD;
&#xD;
          -  Unstabilised coronary disease for at least 6 months&#xD;
&#xD;
          -  Cardiac rhythm trouble or QT space above 550ms without treatment&#xD;
&#xD;
          -  Patient eligible to liver transplant&#xD;
&#xD;
          -  Patient naive of chemiotherapy&#xD;
&#xD;
          -  Patient with a pacemaker, an implanted automatic defibrillator or an automatic&#xD;
             electronic device or an electronic device with metal pieces&#xD;
&#xD;
          -  Patient with contra-indication to the use of NanoKnife system&#xD;
&#xD;
          -  History of hypersensitivity to gadolinium or to iodized contrast product not allowing&#xD;
             a suitable radiologic monitoring&#xD;
&#xD;
          -  Refusal or language or psychic incapacity to sign the informed consent&#xD;
&#xD;
          -  Subject who cannot submit to the constraints of the protocol (subjects for which an&#xD;
             MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not&#xD;
             able to come to the follow-up visits)&#xD;
&#xD;
          -  Concomitant participation to another study&#xD;
&#xD;
          -  Persons benefiting from enhanced protection, namely minors, persons deprived of their&#xD;
             liberty by a judicial or administrative decision, adults under legal protection.&#xD;
&#xD;
          -  Women at age to procreate and not using effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pierre TASU, MD</last_name>
    <phone>+33.5.49.44.44.32</phone>
    <email>jean-pierre.tasu@chu-poitiers.fr</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Irreversible electroporation</keyword>
  <keyword>Interventional radiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

